泰格医药：点评：24Q2业绩环比恢复趋势明显，针对性业务策略推动长期增长

研究报告 Research Report 29 Aug 2024 泰格医药 Hangzhou Tigermed Consulting (300347 CH) 点评： 24Q2 业绩环比恢复趋势明显，针对性业务策略推动长期增长 Review: Obvious Recovery Trend of 24Q2 , Targeted Business Strategies to Promote Long-term Growth | --- | --- | --- | --- | |---------------------------|---------------|------------------------|-------------| | [Table_Info] 维持优于大市 | | | | | 评级 | | 优于大市 | OUTPERFORM | | 现价 | | | Rmb48.68 | | 目标价 | | | Rmb58.46 | | HTI ESG | | | 4.0-3.2-4.5 | | E-S-G: 0-5, | | | | | 义利评级 | | | | | 来源: 盟浪 | | | | | ...